press release: Quest Diagnostics to offer new ovarian cancer test OVA1

Note: no mention of cost

"NEW YORK — Medical lab operator Quest Diagnostics Inc. said Monday it is selling the OVA1 blood test, which aims to better assess a woman's likelihood for ovarian cancer.

The OVA1 test, which was approved by the Food and Drug Administration in September, will be sold through Quest, based in Madison, N.J. The test was developed in collaboration with molecular diagnostics company Vermillion Inc....OVA1 is used as a pre-surgical evaluation of a woman's ovarian mass for cancer. It allows physicians to assess, before a planned surgery, the likelihood that a woman's ovarian mass is malignant. The test allows physicians to direct the patient to a specialist more quickly, the company said.....